Biotech Companies Outsource Antibody-Drug Conjugate Production
High-potency manufacturing requirements drive the majority of antibody-drug conjugate development to external partners.
Updated on Sept. 30, 2026 in Biotech
Live Poll
Do you believe outsourcing drug manufacturing makes advanced medical treatments more accessible to patients?
The global market for antibody-drug conjugates (ADCs) is relying heavily on outsourcing, with 70 to 80 percent of development work managed by external partners. This trend reflects the significant difficulty in maintaining specialized expertise for antibody engineering, linker synthesis, and payload handling within a single organization.
Why it matters
Outsourcing allows biotech firms to bypass the immense capital investment and time required to establish GMP-compliant high-containment facilities. By using integrated development models, companies can concurrently manage antibody production, conjugation, and formulation.
The global ADC market was valued at $14.75 billion in 2024 and is projected to reach approximately $36 billion by 2034. Manufacturing requires specialized site-specific conjugation to attach cytotoxic payloads to defined positions on antibodies.
The details
Manufacturing ADCs involves complex integration of antibodies, chemical linkers, and cytotoxic payloads, often necessitating high-containment infrastructure. Developers utilize integrated models to handle these disparate components simultaneously, creating homogeneous constructs that meet clinical standards.
Timeline
The global ADC market reached a value of $14.75 billion in 2024.
There were more than 200 clinical-stage ADC programs in existence by 2025.
The global ADC market is projected to reach $36 billion by 2034.
The Tech Race
The transition to outsourced ADC manufacturing follows the technical requirements of the high-potency active pharmaceutical ingredient (HPAPI) containment standard. This shift moves the industry away from decentralized internal labs toward specialized, high-containment manufacturing hubs.
For biotech developers and investors, the reliance on external partners shifts the focus toward managing supply chain partnerships rather than physical plant management. This approach lowers the barrier to entry for smaller firms to participate in advanced cancer treatment development.
The takeaway
Biotech companies are increasingly prioritizing partnerships with specialized facilities to handle the complex chemistry of ADCs. This strategy allows firms to scale development efforts more efficiently while avoiding the high costs of building proprietary containment infrastructure.
Further reading
Learn more about the latest innovations and market trends in Biotech.
Source note: This article includes information reported by Pharmafocusasia.
Live Poll
Do you believe outsourcing drug manufacturing makes advanced medical treatments more accessible to patients?
